Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
August 30, 2019 16:05 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals to Present at Two September Healthcare Conferences
August 29, 2019 17:00 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and...
Xeris Pharmaceuticals Announces Second Quarter 2019 Financial Results and Highlights
August 06, 2019 16:05 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and...
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 02, 2019 16:05 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 28, 2019 16:05 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, June 28, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Receives Notification of PDUFA Date Extension for Gvoke™
June 06, 2019 16:05 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, June 06, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces First Quarter 2019 Financial Results and Highlights Its Pipeline
May 09, 2019 16:05 ET
|
Xeris Pharmaceuticals, Inc.
Continuing to execute commercial build and launch readiness for Gvoke HypoPen™ and Gvoke PFS™ Dosed first patient in a Phase 2 study evaluating ready-to-use (RTU) glucagon in EIH Advancing diazepam...
Xeris Pharmaceuticals Announces Results From a Phase 1 Study of Its Novel Formulation of Diazepam
May 01, 2019 08:00 ET
|
Xeris Pharmaceuticals, Inc.
Favorable pharmacokinetic, safety, and tolerability results support continued development of Xeris’ diazepam Phase 2 study to be initiated in 2H2019 CHICAGO, May 01, 2019 (GLOBE NEWSWIRE) -- Xeris...
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 26, 2019 16:01 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, April 26, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
March 29, 2019 16:05 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, March 29, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...